ClinicalTrials.gg
CompletedNCT06320535Updated Oct 21, 2026

A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™

A Phase 1 interventional study of R21/Matrix M™ (Group 1) and R21/Matrix M™ (Group 2) in Malaria,Falciparum, sponsored by University of Oxford. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by University of Oxford · Phase 1, Interventional, and Prevention

How we know

Updated Oct 21, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Malaria, Falciparum by University of Oxford — 3 open to participants now, 9 under way, 1 of them phase 3. Malaria, Falciparum · University of Oxford.

Enrollment
35th of 47
36 · median 62
Started
2024
the only one that year
Phase 1
11 of 54
none open now
Registered
49th of 54
by date

Among the 54 studies in Malaria, Falciparum by University of Oxford, this one is the 35th largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2024, is one of 11 in phase 1, and was the 49th registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

3 of the 54 studies in Malaria, Falciparum by University of Oxford are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Malaria, Falciparum by University of Oxford, or all of them as a file.
02

Study summary

This is a phase I clinical study that aims to assess the safety and immunogenicity of a novel, escalating dose regimen of R21/Matrix-M™ in healthy, malaria-naïve adults.

Read the detailed description

This is a study to assess safety and immunogenicity of a novel dosing regimen for R21/ Matrix-M™, a leading Plasmodium falciparum malaria vaccine, in healthy, malaria-naïve adults. Participants in the study will receive either 6 escalating doses (groups 1 and 2) or 2 standard doses (group 3) of R21/ Matrix-M™, all delivered in the same arm. Up to 36 volunteers will be enrolled and followed up for 12-24 months after their first vaccine.

In addition to blood sampling throughout the follow-up period, participants will undergo fine needle aspiration of axillary lymph nodes twice during the study, to allow further characterisation of immune responses to this novel vaccine regimen.

03

Conditions studied

  • Malaria,Falciparum

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult aged 18 to 50 years.
  • Able and willing (in the Investigator's opinion) to comply with all study requirements.
  • Participants of only: must practice continuous effective until the last study visit.
  • Agreement to refrain from blood donation for the duration of the study.
  • Able and willing to provide written to participate in the trial.

Exclusion criteria

Exclusion Criteria:

  • History of clinical malaria (any species) or previous participation in any malaria vaccine trial or controlled human malaria infection trial.
  • Travel to a clearly malaria endemic locality during the study period or within the preceding six months, as per the CDC website: https://www.cdc.gov/malaria/travelers/country_table/a.html
  • Participation in another research study involving receipt of an medicinal product (IMP) in the 30 days preceding enrolment or 5 half-lives of the investigational medicinal product, whichever is longer, or planned participation during the study period.
  • Prior receipt of an IMP likely to impact interpretation of the trial data, as assessed by the Investigator.
  • Receipt of any vaccine within 30 days of a study vaccine, with the exception of COVID-19 vaccination.
  • Receipt of oral or systemic medication for more than 14 days in the six months preceding enrolment.
  • Receipt of immunoglobulins or blood products (e.g. blood transfusion) in the three months preceding enrolment.
  • History of anaphylaxis to vaccination, or allergy likely to be exacerbated by any component of the vaccine or study procedures, including allergy to lidocaine
  • Pregnancy, lactation or intention to become pregnant during the study.
  • history of chronic disease, including cancer (except basal cell carcinoma or cervical carcinoma in situ), immunodeficiency (including ), conditions (except mild psoriasis, well-controlled autoimmune thyroid disease, vitiligo or stable coeliac disease), psychiatric disorder, drug or alcohol abuse
  • Positive surface antigen (HBsAg), HIV antibodies or (HCV) antibodies (except previous HCV vaccine study participants)
  • HEMStop score > or = to 2(30) with abnormal coagulation screen or clinical concern regarding bleeding risk.
  • Use of medications that increase the risk of bleeding, as assessed by the clinician, including: warfarin, oral antithrombin agents (e.g. Apixaban), low molecular weight heparin
  • Any clinically significant abnormality of screening examination, blood or urine tests
  • Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may put the volunteer at risk, affect the volunteer's ability to participate in the study or impair interpretation of the study data
  • Participants unable to be closely followed for social, geographic or psychological reasons.
  • Investigator inability to corroborate a participant's medical history via access to NHS electronic records and/or their GP.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Group 1: Escalating dose R21/Matrix M™

    12 volunteers receiving escalating doses of R21/Matrix M™ adjuvant at days 0, 3, 7, 10, 14, and 56 via intramuscular (IM) injection in the deltoid region of the same arm

    Biological: R21/Matrix M™ (Group 1) · Procedure: Fine needle aspiration (FNA)

  • Experimental
    Group 2: Escalating dose R21/Matrix M™ with delayed booster

    12 volunteers receiving escalating doses of R21/Matrix M™ adjuvant at days 0, 3, 7, 10, 14, 168 (subgroup 2A)/280 (subgroup 2B) via intramuscular (IM) injection in the deltoid region of the same arm

    Biological: R21/Matrix M™ (Group 2) · Procedure: Fine needle aspiration (FNA)

  • Experimental
    Group 3: Standard dose R21/Matrix-M™

    12 volunteers receiving two 10mcg doses of R21 in 50mcg of Matrix M™ adjuvant at days 0 and 56 via intramuscular (IM) injection in the deltoid region of the same arm

    Biological: R21/Matrix M™ (Group 3) · Procedure: Fine needle aspiration (FNA)

Interventions

  • BiologicalR21/Matrix M™ (Group 1)

    Drug page: Matrix-MStudies of Matrix-MMatrix-M pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    * 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0) * 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3) * 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7) * 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10) * 5 mcg R21 in 25 mcg Matrix-M™ (D14) * 10 mcg R21 in 50 mcg Matrix-M™ (D56)

  • BiologicalR21/Matrix M™ (Group 2)

    Drug page: Matrix-MStudies of Matrix-MMatrix-M pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Group 2A: * 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0) * 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3) * 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7) * 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10) * 5 mcg R21 in 25 mcg Matrix-M™ (D14) * 10 mcg R21 in 50 mcg Matrix-M™(D168) Group 2B: * 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0) * 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3) * 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7) * 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10) * 5 mcg R21 in 25 mcg Matrix-M™ (D14) * 10 mcg R21 in 50 mcg Matrix-M™(D280)

  • BiologicalR21/Matrix M™ (Group 3)

    Drug page: Matrix-MStudies of Matrix-MMatrix-M pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    * 10 mcg R21 in 50 mcg Matrix-M™ (D0) * 10 mcg R21 in 50 mcg Matrix-M™ (D56)

  • ProcedureFine needle aspiration (FNA)

    Participants in all groups will undergo fine needle aspiration (FNA) of axillary lymph nodes draining vaccination site on Day 77 and Day 105 after initial vaccination.

06

What researchers measure

Primary outcomes

  1. Safety of R21/Matrix-M™ administered in an escalating dose, multi prime vaccination schedule versus a standard prime-boost regimen in healthy UK adults, measured by the number of solicited adverse events in each group

    Occurrence of solicited local and systemic reactogenicity signs and symptoms will be collected for 7 days following each vaccination. Solicited adverse event data will be tabulated, detailing frequency, duration and severity of the AEs.

    Time frame: 7 days post-vaccination

  2. Safety of R21/Matrix-M™ administered in an escalating dose, multi prime vaccination schedule versus a standard prime-boost regimen in healthy UK adults, measured by the number of unsolicited adverse events and laboratory adverse events in each group

    Occurrence of unsolicited adverse events and changes from baseline in laboratory safety measures will be collected for 28 days following each vaccination. Unsolicited AE data will be tabulated, detailing frequency, duration and severity of AEs. Hematological and biochemical laboratory values will be presented according to local grading scales.

    Time frame: 28 days post-vaccination.

  3. Safety of R21/Matrix-M™ administered in an escalating dose, multi prime vaccination schedule versus a standard prime-boost regimen in healthy UK adults, measured by the number of serious adverse events in each group

    Occurrence of serious adverse events (SAEs), adverse events of special interest (AESIs) and withdrawal due to AE(s)/SAE(s) will be described in detail.

    Time frame: For the follow-up period of the study, between 1-2 years

  4. Humoral immunogenicity of R21/Matrix-M™ administered in an escalating dose, multi-prime vaccination schedule verus a standard prime-boost regimen in healthy UK adults

    Antibody dynamics will be assessed by measuring NANP-IgG at baseline and various timepoints during the trial.

    Time frame: For the follow-up period of the study, between 1-2 years

Other outcomes

  1. Impact of vaccination schedule on immune response in participants vaccinated with R21/Matrix-M™ administered in escalating dose, multi-prime vaccination schedules versus a standard prime-boost regimen

    (Exploratory outcome measure) Exploratory immunology to further investigate the relationship between cellular and humoral immunity and vaccine regimen.

    Time frame: For the follow-up period of the study, between 1-2 years

07

Study locations

2 sites
  • Centre for Clinical Vaccinology and Tropical Meducine, Churchill Hospital, University of Oxford
    Oxford, Oxfordshire OX3 7LE, United Kingdom
  • University Hospitals Bristol and Weston NHS Foundation Trust
    Bristol, BS2 8HW, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Sep 2026, 29 months.

Of 29 non-industry phase 1 interventional studies under Malaria, Falciparum, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's 29 months is above that.

Counting every sponsor, half of 49 studies reached it within 13 months; a quarter within 7 and three quarters within 18.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Jun 2026 → Sep 2026 and completion Jun 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2024
First posted
Mar 20, 2024
StartActual
Mar 25, 2024
Primary completionActual
Sep 1, 2026was Jun 2026
CompletionActual
Sep 1, 2026was Jun 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 21, 2026
Primary completion
Jun 2026→Sep 1, 2026 (actual)
Oct 21, 2026
Study completion
Jun 2027→Sep 1, 2026 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Active, not recruiting→Completed
    Primary completion Jun 2026→Sep 1, 2026 (now actual)
    Study completion Jun 2027→Sep 1, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06320535
Collaborators
Bill and Melinda Gates Foundation, University Hospitals Bristol and Weston NHS Foundation Trust
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
Mar 25, 2024
Primary completion
Sep 1, 2026
Completion
Sep 1, 2026
Last update
Oct 21, 2026

Study contacts

Susanne Hodgson, DPhil FRCP
principal investigator · Center for Clinical Vaccinology and Tropical Medicine, University of Oxford
Rajeka Lazarus, DPhil FRCP
principal investigator · University Hospitals Bristol and Weston Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Matrix-M

Start the discussion